Avillion LLP gets initial funding from Abingworth, Clarus Ventures

By Admin
Avillion LLP, which focuses on clinical co-development of therapeutics, has said it has secured initial funding from A...

Avillion LLP, which focuses on clinical co-development of therapeutics, has said it has secured initial funding from Abingworth LLP and Clarus Ventures. UK-based Avillion is partnering with pharmaceutical and biotechnology companies to co-develop and finance late stage therapeutics.

The company will use its clinical development and regulatory expertise to get the global approvals for a broad range of drugs and biologics. 

Lewis Cameron, CEO of Avillion said, “Avillion offers pharma and biotech companies compelling option to collaborate late stage drug approval projects globally. “ Mr. Cameron also said, “We have an experienced team focused on global drug development and approval, with the capability to optimize CRO management.”  

The management team is led by Lewis Cameron who has held senior positions in CRO companies including Chiltern International, Clearstone and LabCorp, Dr Allison Jeynes-Ellis has more than 20 years’ experience running clinical trials for pharmaceutical companies like BMS and Wyeth.

It has also been extensively involved in health technology appraisals across various countries.  Graham Higson (VP, Regulatory) has three decades of regulatory experience, including 5 years as the global head of regulatory affairs at AstraZeneca.  Abingworth  is a global investment group dedicated mainly to the life sciences and healthcare sector.

The company invests at all stages of development including early and late-stage venture financing, growth equity and public companies.  

Clarus Ventures is a life sciences venture capital company founded by a team of accomplished investment and operating professionals. 

Share
Share

Featured Articles

Healthcare Business roundup: Baxter, Sanofi & Eli Lilly

Baxter International to sell kidney care spin-off Vantive; Sanofi's consumer health unit ‘to be separated’; Eli Lilly to buy Morphic Holding for $3.2bn

Trane Technologies Helping US Hospitals Meet Climate Pledge

Christy Fetsch of Trane Technologies explains how the company is helping US hospitals meet White House sustainability pledges for US healthcare provision

Nestlé Health Science Targets Weight Loss Side-Effects

Nestlé Health Science launches nutrition initiative to counteract side effects of weight-loss drugs, including hollowed-out 'Ozempic Face'

Eli Lilly Alzheimer's Drug Kisunla Approved in US by FDA

Medical Devices & Pharma

WEF: Gender Health Gap 'Costs women 75mn years of Life'

Medical Devices & Pharma

Schneider: Swathe of NHS Failing to Measure Sustainability

Sustainability